HLB Co. Ltd

KQ:028300 Korea Biotechnology
Market Cap
$4.54 Billion
₩6.65 Trillion KRW
Market Cap Rank
#3205 Global
#61 in Korea
Share Price
₩50700.00
Change (1 day)
+4.00%
52-Week Range
₩37000.00 - ₩71900.00
All Time High
₩120800.00
Categories
Companies in Korea Biotechnology
About

HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, inclu… Read more

HLB Co. Ltd (028300) - Net Assets

Latest net assets as of September 2025: ₩452.86 Billion KRW

Based on the latest financial reports, HLB Co. Ltd (028300) has net assets worth ₩452.86 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩703.48 Billion) and total liabilities (₩250.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩452.86 Billion
% of Total Assets 64.37%
Annual Growth Rate 23.94%
5-Year Change 20.18%
10-Year Change 581.12%
Growth Volatility 77.77

HLB Co. Ltd - Net Assets Trend (2005–2024)

This chart illustrates how HLB Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for HLB Co. Ltd (2005–2024)

The table below shows the annual net assets of HLB Co. Ltd from 2005 to 2024.

Year Net Assets Change
2024-12-31 ₩576.57 Billion -0.97%
2023-12-31 ₩582.25 Billion -8.73%
2022-12-31 ₩637.94 Billion +46.33%
2021-12-31 ₩435.96 Billion -9.13%
2020-12-31 ₩479.75 Billion +159.48%
2019-12-31 ₩184.89 Billion +5.84%
2018-12-31 ₩174.68 Billion +126.15%
2017-12-31 ₩77.24 Billion -12.97%
2016-12-31 ₩88.75 Billion +4.84%
2015-12-31 ₩84.65 Billion +267.72%
2014-12-31 ₩23.02 Billion +48.49%
2013-12-31 ₩15.50 Billion -16.67%
2012-12-31 ₩18.60 Billion -12.21%
2011-12-31 ₩21.19 Billion -9.07%
2010-12-31 ₩23.31 Billion -49.84%
2009-12-31 ₩46.46 Billion +7.26%
2008-12-31 ₩43.32 Billion +123.57%
2007-12-31 ₩19.38 Billion -0.31%
2006-12-31 ₩19.44 Billion +98.91%
2005-12-31 ₩9.77 Billion --

Equity Component Analysis

This analysis shows how different components contribute to HLB Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 21193449096000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩211.93 Billion 36.76%
Common Stock ₩65.69 Billion 11.39%
Other Components ₩298.94 Billion 51.85%
Total Equity ₩576.57 Billion 100.00%

HLB Co. Ltd Competitors by Market Cap

The table below lists competitors of HLB Co. Ltd ranked by their market capitalization.

Company Market Cap
DAWUF
PINK:DAWUF
 		$4.12 Billion
Shandong Himile Mechanical Science & Technology Co Ltd
SHE:002595
 		$4.12 Billion
Universal Display
NASDAQ:OLED
 		$4.12 Billion
Andritz AG
PINK:ADRZF
 		$4.12 Billion
Grupo Bimbo S.A.B. De C.V.
PINK:GRBMF
 		$4.11 Billion
ATGPF
PINK:ATGPF
 		$4.11 Billion
Rational AG
LSE:0FRJ
 		$4.11 Billion
GLOBALFOUNDR. INC. DL-02
F:76J
 		$4.11 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HLB Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 523,885,541,070 to 576,572,200,390, a change of 52,686,659,320 (10.1%).
  • Net loss of 91,980,166,750 reduced equity.
  • Share repurchases of 2,012,888,320 reduced equity.
  • New share issuances of 2,012,888,320 increased equity.
  • Other factors increased equity by 144,666,826,070.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩-91.98 Billion -15.95%
Share Repurchases ₩2.01 Billion -0.35%
Share Issuances ₩2.01 Billion +0.35%
Other Changes ₩144.67 Billion +25.09%
Total Change ₩- 10.06%

Book Value vs Market Value Analysis

This analysis compares HLB Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 11.53x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 46.02x to 11.53x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩1101.67 ₩50700.00 x
2017-12-31 ₩945.50 ₩50700.00 x
2018-12-31 ₩1980.23 ₩50700.00 x
2019-12-31 ₩1920.62 ₩50700.00 x
2020-12-31 ₩4539.18 ₩50700.00 x
2021-12-31 ₩4094.41 ₩50700.00 x
2022-12-31 ₩5222.63 ₩50700.00 x
2023-12-31 ₩4069.69 ₩50700.00 x
2024-12-31 ₩4396.90 ₩50700.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HLB Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -15.95%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -135.02%
  • • Asset Turnover: 0.08x
  • • Equity Multiplier: 1.54x
  • Recent ROE (-15.95%) is below the historical average (-13.30%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 -12.22% -7.88% 0.69x 2.26x ₩-5.33 Billion
2015 14.93% 32.86% 0.21x 2.19x ₩4.17 Billion
2016 -14.89% -43.85% 0.16x 2.10x ₩-22.09 Billion
2017 -21.40% -71.85% 0.12x 2.44x ₩-24.25 Billion
2018 14.51% 70.04% 0.12x 1.74x ₩7.87 Billion
2019 -24.01% -115.53% 0.11x 1.96x ₩-62.88 Billion
2020 -16.69% -142.57% 0.08x 1.47x ₩-128.07 Billion
2021 -22.51% -140.53% 0.09x 1.71x ₩-141.72 Billion
2022 -12.25% -43.49% 0.19x 1.52x ₩-141.95 Billion
2023 -35.80% -437.17% 0.06x 1.43x ₩-239.94 Billion
2024 -15.95% -135.02% 0.08x 1.54x ₩-149.64 Billion

Industry Comparison

This section compares HLB Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $224,406,467,813
  • Average return on equity (ROE) among peers: -9.25%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HLB Co. Ltd (028300) ₩452.86 Billion -12.22% 0.55x $4.11 Billion
ORIENTBIO Inc. (002630) $67.35 Billion -2.60% 1.21x $28.10 Million
Green Cross (005250) $282.15 Billion 18.83% 0.53x $228.88 Million
Green Cross Holdings Preference Shares (005257) $1.44 Trillion 3.01% 0.78x $410.72 Million
Pharmicell (005690) $9.90 Billion -119.73% 2.00x $438.14 Million
GeneOne Life Science Inc (011000) $39.74 Billion 0.00% 0.49x $53.78 Million
Daesung Microbiological Labs. Co. Ltd (036480) $25.09 Billion 18.13% 0.29x $14.92 Million
Seoulin Bioscience Co.Ltd (038070) $51.49 Billion 4.00% 0.38x $27.72 Million
Hyundai Bioscience Co. Ltd (048410) $39.30 Billion 0.00% 0.56x $899.28 Million
iNtRON Biotechnology Inc (048530) $64.96 Billion -4.91% 0.37x $83.99 Million